pharmaphorum Podcast
By pharmaphorum
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by pharmaphorum
Category: Life Sciences
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 5
Reviews: 0
Episodes: 181
Description
pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for those who want insight into the future of health and medicine.
| Episode | Date |
|---|---|
|
Clinical trials: their design, location, and, potentially, their simulation
|
May 08, 2024 |
|
Pace, acceleration, and precision are the name of the game
|
May 02, 2024 |
|
Technology working as the puzzle piece to bring better outcomes to patients
|
Apr 30, 2024 |
|
Is precision psychiatry possible?
|
Apr 25, 2024 |
|
Encouraging early engagement to revitalise Europe’s pharmaceutical landscape
|
Apr 23, 2024 |
|
Predictions for AI in mental health in the coming year
|
Apr 18, 2024 |
|
Fixing clinical trial data management
|
Apr 11, 2024 |
|
Harnessing the velocity of biopharmaceutical advances
|
Apr 09, 2024 |
|
Conference report: Reuters Pharma USA
|
Apr 04, 2024 |
|
The future of AI: Machine learning working together with scientific expertise
|
Apr 02, 2024 |
|
Understanding the politics of drug pricing in the United States
|
Mar 28, 2024 |
|
Female leadership and lessening disease burden
|
Mar 26, 2024 |
|
The unique clinical trial challenges faced by digital therapeutics
|
Mar 21, 2024 |
|
The unmentionables: Challenging inequalities in women’s health
|
Mar 19, 2024 |
|
The next chapter for AI protein structure prediction
|
Mar 14, 2024 |
|
Avoiding the data swamp: The transformative power of AI
|
Mar 12, 2024 |
|
How natural language processing can make a difference in pharma
|
Mar 07, 2024 |
|
Transitioning from traditional surgical methods to the innovative use of stem cells.
|
Mar 05, 2024 |
|
The 2024 biopharma M&A landscape: An overview
|
Feb 29, 2024 |
|
Accelerating the process, transforming therapies and advancing precision medicine
|
Feb 27, 2024 |
|
Applying genetics to chemistry to find new small molecules
|
Feb 22, 2024 |
|
Opening the digital front door to advanced healthcare
|
Feb 20, 2024 |
|
Pharmaceutical research in space
|
Feb 15, 2024 |
|
Precision medicine in mental health - one size really doesn’t fit all
|
Feb 13, 2024 |
|
Where are the pharma voices in US politics?
|
Feb 08, 2024 |
|
A clearer harmony and attractiveness for EU Clinical Trials Regulation
|
Feb 06, 2024 |
|
Making connections and getting noticed as a biotech start-up
|
Feb 01, 2024 |
|
Getting down to the nitty gritty of actively creating healthier societies
|
Jan 30, 2024 |
|
How manufacturing keeps pace with innovation in cell and gene therapy
|
Jan 25, 2024 |
|
Fixing the inequity of drug access outside of the US
|
Jan 23, 2024 |
|
Key themes from JP Morgan
|
Jan 18, 2024 |
|
Prediction is very difficult, especially if it’s about the future
|
Jan 16, 2024 |
|
Promoting value-added medicines and renovating old medicines smartly
|
Jan 11, 2024 |
|
Digitisation of drug R&D: Avoiding new for novelty’s sake
|
Jan 09, 2024 |
|
The problems of animal research for human medicine and the alternatives
|
Jan 04, 2024 |
|
The race to develop innovative products and supply chain solutions
|
Dec 30, 2023 |
|
The smart-design evolution of the laboratory space
|
Dec 29, 2023 |
|
Investing in the gleams of positivity and hope for life sciences innovation
|
Dec 28, 2023 |
|
Looking to the future of UK medical device exports
|
Dec 27, 2023 |
|
Exploring the reasons behind increasing burdens on clinical research sites
|
Dec 26, 2023 |
|
An investor’s perspective on bio and tech
|
Dec 21, 2023 |
|
Why digital therapeutics (DTx) are effective and safe, but not being prescribed
|
Dec 19, 2023 |
|
AI drug discovery: Where we are and where we’re going
|
Dec 14, 2023 |
|
Retaining the human element in healthcare services whilst embracing the potential of robotics
|
Dec 12, 2023 |
|
Bringing women’s health up to speed for 21st Century human healthcare
|
Dec 07, 2023 |
|
Creating a future where the healthcare ecosystem works for everyone
|
Dec 05, 2023 |
|
Key themes from Frontiers Health 2023, with the pharmaphorum team
|
Nov 30, 2023 |
|
Reducing the stigma attached to psychedelics
|
Nov 28, 2023 |
|
How birth tissue donations are fuelling the cell therapy revolution
|
Nov 23, 2023 |
|
Immunometabolism: Providing a new era of targeted medicine
|
Nov 21, 2023 |
|
Retaining the human element of AI within pharma and healthcare
|
Nov 16, 2023 |
|
Resilience, empathy, and gratitude. A personal battle with breast cancer.
|
Nov 14, 2023 |
|
The ‘elegant science’ in achieving the promise of ADCs
|
Nov 07, 2023 |
|
Understanding the importance of the whole person in clinical research
|
Nov 02, 2023 |
|
Why medical weight loss is more complicated than GLP-1s
|
Oct 27, 2023 |
|
Creating behavioural change through incremental, small steps
|
Oct 24, 2023 |
|
How AI can bolster each step of the clinical trial journey
|
Oct 19, 2023 |
|
Focussing on finding value in health sciences marketing
|
Oct 17, 2023 |
|
How big pharma cares for its own
|
Oct 12, 2023 |
|
Embracing the challenges and opportunities of digital health
|
Oct 10, 2023 |
|
How AI and omnichannel are transforming pharma marketing
|
Oct 05, 2023 |
|
Digital therapeutics at a turning point: What we heard at DtX East
|
Oct 03, 2023 |
|
Understanding and addressing care disparities in rare cancers
|
Sep 28, 2023 |
|
Turning drug development on its head
|
Sep 21, 2023 |
|
GLP-1 Weight loss drugs: An overview and update
|
Sep 14, 2023 |
|
Biopharma’s rapid transition to omnichannel marketing
|
Sep 07, 2023 |
|
Partnering for holistic care
|
Aug 31, 2023 |
|
Mapping the landscape of clinical trial regulation
|
Aug 25, 2023 |
|
Preparing for the tsunami of healthcare data approaching
|
Aug 15, 2023 |
|
Alzheimer’s drugs: An overview and update
|
Aug 10, 2023 |
|
Suffering beyond physical effects: inequalities and taboos in prostate cancer
|
Aug 01, 2023 |
|
Collaborative perseverance to bring change to medicine access
|
Jul 28, 2023 |
|
Botanicals in pharma: Potential and pitfalls
|
Jul 27, 2023 |
|
Clinical trial diversity: An update
|
Jul 13, 2023 |
|
Changing personnel dynamics in the pharma world
|
Jul 06, 2023 |
|
Retaining the human quality of healthcare in DTx
|
Jul 05, 2023 |
|
Focusing on predictability and execution in digital trials
|
Jun 28, 2023 |
|
Genetic testing update with 23andMe’s Noura Abul-Husn
|
Jun 16, 2023 |
|
Headlines and hot topics from ASCO and BIO
|
Jun 09, 2023 |
|
The precision element at the heart of digital transformation
|
May 30, 2023 |
|
AI in drug development: A reality check
|
May 25, 2023 |
|
Epiphany moments in an industry starved of insights
|
May 22, 2023 |
|
A closer look at gene therapy with PTC Therapeutics
|
May 18, 2023 |
|
WWD: Ready, Set, Food! CEO, Daniel Zakowski
|
May 11, 2023 |
|
The Hidden Burden of Stigmatised Health Conditions
|
May 02, 2023 |
|
Creating healthier futures - Reuters Pharma Barcelona 2023
|
May 02, 2023 |
|
Inside the new world of healthcare data
|
Apr 20, 2023 |
|
Restoring sensitivity to targeted therapies
|
Apr 14, 2023 |
|
Insulin costs & pharma manufacturing
|
Apr 13, 2023 |
|
What the low impact of Humira biosimilars teaches us about drug prices
|
Apr 06, 2023 |
|
Transforming healthcare: Nils Bottler and Paul Tunnah
|
Mar 30, 2023 |
|
Challenges and opportunities with plasma-derived therapies
|
Mar 23, 2023 |
|
CinCor Pharma: A small pharma’s journey to acquisition
|
Mar 10, 2023 |
|
AI trends in 2023
|
Mar 02, 2023 |
|
Accelerating digital healthcare, with VITA
|
Mar 01, 2023 |
|
Investing in healthcare’s future, with Paul Tunnah and Elia Stupka
|
Feb 17, 2023 |
|
Solving problems in pathology data, with Nathan Buchbinder
|
Feb 09, 2023 |
|
How Moderna kept diversity in mind amid vaccine development
|
Jan 26, 2023 |
|
Key themes from JP Morgan, with Paul Tunnah
|
Jan 12, 2023 |
|
Cancer control in a time of crisis
|
Jan 05, 2023 |
|
The scattered seeds of the beginnings of change
|
Dec 30, 2022 |
|
A few of the 2022’s biggest pharma trends
|
Dec 29, 2022 |
|
Exploring the importance we play in our own health maintenance
|
Dec 23, 2022 |
|
Focusing on the evolution of biotechnology and R&D
|
Dec 22, 2022 |
|
Innovations in Real-World Evidence (live from PharmStars)
|
Dec 15, 2022 |
|
Continuing to keep COVID-19 at bay
|
Dec 08, 2022 |
|
Can VR technology make physical therapy fun
|
Dec 01, 2022 |
|
Exploring a united vision for British pharma at Anthropy
|
Nov 28, 2022 |
|
What we heard and saw at HLTH22, with Matthew Holt
|
Nov 24, 2022 |
|
Disrupting the standard of healthcare for Bangladesh
|
Nov 18, 2022 |
|
How immersive audio can be a therapeutic tool
|
Nov 17, 2022 |
|
A new hope in cachexia and an outsider’s view on pharma
|
Nov 10, 2022 |
|
Why is digital health so challenging for big tech?
|
Nov 03, 2022 |
|
Live from Frontiers Health 2022 - the pharmaphorum podcast
|
Oct 27, 2022 |
|
Live from Reuters Pharma 2022 - the pharmaphorum podcast
|
Oct 20, 2022 |
|
Building agile partner relationships at a vaccine-focused biotech
|
Oct 13, 2022 |
|
Understanding the tumour micro-environment – the pharmaphorum podcast
|
Oct 06, 2022 |
|
How a once-weekly insulin could disrupt diabetes management
|
Sep 22, 2022 |
|
How these parents of a child with a rare disease are making precision medicine work for them
|
Sep 08, 2022 |
|
AI-derived cancer vaccines
|
Aug 25, 2022 |
|
Challenges and opportunities in the off-patent sector
|
Aug 11, 2022 |
|
Building a digital therapeutic for paediatric behavioural health opioids
|
Jul 28, 2022 |
|
Gene silencing and mRNA: breakthroughs and barriers
|
Jul 14, 2022 |
|
Rethinking pharmaceutical pain management beyond opioids
|
Jul 05, 2022 |
|
Why diverse clinical trials matter
|
Jun 16, 2022 |
|
Where pharma stands on patient centricity, engagement, and trust
|
Jun 06, 2022 |
|
How pharma can spur innovation and promote health equity in mental health
|
May 19, 2022 |
|
Innovative solutions to the drug pricing crisis: the pharmaphorum podcast
|
Apr 29, 2022 |
|
Big data and how it can change the game in pharma: the pharmaphorum podcast
|
Mar 23, 2022 |
|
The year ahead in digital health and life sciences: the pharmaphorum podcast
|
Feb 10, 2022 |
|
The evolution of clinical trials: the pharmaphorum podcast
|
Jan 14, 2022 |
|
Patient engagement processes: the pharmaphorum podcast
|
Dec 17, 2021 |
|
Real-world evidence and qualitative research: the ELICIT podcast
|
Nov 25, 2021 |
|
Merck on trends in oncology: the pharmaphorum podcast
|
Nov 12, 2021 |
|
Sandoz’s Pierre Bourdage on biosimilars: the pharmaphorum podcast
|
Nov 05, 2021 |
|
Patient engagement strategies: the pharmaphorum podcast
|
Oct 29, 2021 |
|
BMS’ Catherine Owen on pharma commercialisation: the pharmaphorum podcast
|
Oct 15, 2021 |
|
Novartis’ Amit Nastik on COVID’s supply chain impact: the pharmaphorum podcast
|
Oct 04, 2021 |
|
Virtual engagement and collaborations: the pharmaphorum podcast
|
Sep 22, 2021 |
|
Biotech Insight podcast: Overcoming planning challenges in oncology
|
Sep 08, 2021 |
|
Vertex senior country manager Nicola Massey: the pharmaphorum podcast
|
Aug 23, 2021 |
|
Regenerative medicine and COVID: the pharmaphorum podcast
|
Aug 13, 2021 |
|
Pharmacy and clinical research: the pharmaphorum podcast
|
Jun 30, 2021 |
|
Pharma’s post-COVID prospects: the pharmaphorum podcast
|
May 28, 2021 |
|
Galapagos UK’s Michael Smyth on COVID and RNA-based tech: the pharmaphorum podcast
|
Apr 30, 2021 |
|
Big data and cell therapy development: the pharmaphorum podcast
|
Apr 20, 2021 |
|
GSK on COVID and vaccine development: the pharmaphorum podcast
|
Mar 31, 2021 |
|
The meaning of digital innovation: the pharmaphorum podcast
|
Mar 23, 2021 |
|
New ways to treat COVID: the pharmaphorum podcast
|
Mar 12, 2021 |
|
The Alderley Park Discovery Podcast: The journey to accessing science funding and investment
|
Mar 08, 2021 |
|
Roche on COVID healthcare and testing: the pharmaphorum podcast
|
Feb 26, 2021 |
|
Richard Francis discusses his new role as Purespring’s CEO: pharmaphorum podcast
|
Feb 12, 2021 |
|
AstraZeneca’s Rebekah Martin on diversity and inclusion: the pharmaphorum podcast
|
Jan 29, 2021 |
|
The Alderley Park Discovery Podcast: Life science skills, staffing and support
|
Jan 05, 2021 |
|
J&J and medical device innovation: the pharmaphorum podcast
|
Dec 21, 2020 |
|
Biotech trends in COVID era: the pharmaphorum podcast
|
Nov 30, 2020 |
|
GSK and eosinophil research: the pharmaphorum podcast
|
Oct 30, 2020 |
|
Gitte Aabo on telemedicine and her time at LEO Pharma: the pharmaphorum podcast
|
Sep 28, 2020 |
|
The Alderley Park Discovery Podcast: COVID testing and the Lighthouse Lab
|
Sep 15, 2020 |
|
Alnylam, gene-silencing and biotech in 2020: the pharmaphorum podcast
|
Aug 27, 2020 |
|
Novartis, company culture and COVID-19: the pharmaphorum podcast
|
Jul 30, 2020 |
|
Amgen and science education: the pharmaphorum podcast
|
Jun 30, 2020 |
|
UK pharma leadership and COVID-19: the pharmaphorum podcast
|
May 29, 2020 |
|
Eisai and Alexa skills in epilepsy: the pharmaphorum podcast
|
Apr 02, 2020 |
|
Digital health and interoperability: the pharmaphorum podcast
|
Mar 09, 2020 |
|
Roche, big data and patient outcomes: the pharmaphorum podcast
|
Jan 08, 2020 |
|
Pfizer and the UK cancer landscape: the pharmaphorum podcast
|
Dec 11, 2019 |
|
Life sciences leadership: the pharmaphorum podcast
|
Nov 14, 2019 |
|
AstraZeneca and lung cancer: the pharmaphorum podcast
|
Aug 07, 2019 |
|
Lung cancer’s patient information gap: the pharmaphorum podcast
|
Aug 06, 2019 |
|
The state of UK drug discovery: the pharmaphorum podcast
|
Jul 19, 2019 |
|
Addressing global health challenges: the pharmaphorum podcast
|
Jun 19, 2019 |
|
Gene therapy and market access: the pharmaphorum podcast
|
May 31, 2019 |
|
AMR research and Matoke Pharma: the pharmaphorum podcast
|
May 13, 2019 |
|
GSK and digital disruption: the pharmaphorum podcast
|
Apr 05, 2019 |
|
Ipsen on neurotoxin research: the pharmaphorum podcast
|
Mar 28, 2019 |
|
Successful medical marketing teams: the pharmaphorum podcast
|
Feb 22, 2019 |
|
Biotech strategy and nanomedicine: the pharmaphorum podcast
|
Dec 21, 2018 |
|
Commercialising orphan drugs: the pharmaphorum podcast
|
Nov 20, 2018 |
|
The future biosimilar landscape: the pharmaphorum podcast
|
Oct 16, 2018 |
|
Nimble consumer healthcare innovation: the pharmaphorum podcast
|
Sep 14, 2018 |